What was the overall market valuation of the US dercums disease market in 2024?

The overall market valuation was $2795.73 Million in 2024. Read More

What is the projected market valuation for the US dercums disease market by 2035?

The projected valuation for 2035 is $5742.24 Million. Read More

What is the expected CAGR for the US dercums disease market during the forecast period 2025 - 2035?

The expected CAGR for the market during this period is 6.76%. Read More

Which companies are considered key players in the US dercums disease market?

Key players include AstraZeneca, Novartis, Pfizer, Bristol-Myers Squibb, Roche, Sanofi, Eli Lilly and Company, and Amgen. Read More

What was the market size for the Medication segment in 2024?

The market size for the Medication segment was $558.15 Million in 2024. Read More

What is the projected market size for Hospital & Clinics as an end user by 2035?

The projected market size for Hospital & Clinics as an end user is $2330.0 Million by 2035. Read More

How does the market size for Retail Pharmacies compare to Hospital Pharmacies in 2024?

In 2024, Retail Pharmacies had a market size of $1394.3 Million, while Hospital Pharmacies had $1118.29 Million. Read More

What is the projected market size for the Liposuction treatment segment by 2035?

The projected market size for the Liposuction treatment segment is $1148.44 Million by 2035. Read More

What is the expected growth trend for the US dercums disease market in the coming years?

The market is expected to grow steadily, driven by a CAGR of 6.76% from 2025 to 2035. Read More

US Dercums Disease Market

Q: What are the main treatment segments in the US dercums disease market?

Main treatment segments include Surgery, Medication, Liposuction, Electrotherapy, Acupuncture, and Others. Read More

ID: MRFR/HC/47425-HCR

200 Pages

Rahul Gotadki

Last Updated: April 06, 2026

US Dercum's Disease Market Research Report By Treatment (Surgery, Medication, Liposuction, Electrotherapy, Acupuncture, Others), By End user (Hospital & Clinics, Ambulatory Surgical Centers, Others) andBy Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) - Growth & Industry Forecast 2025 To 2035

US Dercums Disease Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)6.76%

2024 Market Size$ 2,795.73 Million

2025 Market Size$ 2,984.72 Million

2035 Market Size$ 5,742.24 Million

Key Players

AstraZeneca

Novartis

Pfizer

Bristol-Myers Squibb

Roche

Sanofi

Trends

Increased Awareness and Diagnosis
Advancements in Treatment Options
Role of Patient Advocacy Groups

Opportunities

Increased Research Funding
Rising Patient Advocacy Efforts
Expansion of Treatment Facilities

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Treatment (USD Million)
  1. 4.1.1 Surgery
  2. 4.1.2 Medication
  3. 4.1.3 Liposuction
  4. 4.1.4 Electrotherapy
  5. 4.1.5 Acupuncture
  6. 4.1.6 Others
2. 4.2 Construction, BY End User (USD Million)
  1. 4.2.1 Hospital & Clinics
  2. 4.2.2 Ambulatory Surgical Centers
  3. 4.2.3 Others
3. 4.3 Construction, BY Distribution Channel (USD Million)
  1. 4.3.1 Hospital Pharmacies
  2. 4.3.2 Retail Pharmacies
  3. 4.3.3 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 AstraZeneca (GB)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Novartis (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Pfizer (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bristol-Myers Squibb (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Roche (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Sanofi (FR)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Eli Lilly and Company (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Amgen (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TREATMENT
3. 6.3 US MARKET ANALYSIS BY END USER
4. 6.4 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
5. 6.5 KEY BUYING CRITERIA OF CONSTRUCTION
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF CONSTRUCTION
8. 6.8 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
9. 6.9 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 SUPPLY / VALUE CHAIN: CONSTRUCTION
11. 6.11 CONSTRUCTION, BY TREATMENT, 2024 (% SHARE)
12. 6.12 CONSTRUCTION, BY TREATMENT, 2024 TO 2035 (USD Million)
13. 6.13 CONSTRUCTION, BY END USER, 2024 (% SHARE)
14. 6.14 CONSTRUCTION, BY END USER, 2024 TO 2035 (USD Million)
15. 6.15 CONSTRUCTION, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
16. 6.16 CONSTRUCTION, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TREATMENT, 2025-2035 (USD Million)
  2. 7.2.2 BY END USER, 2025-2035 (USD Million)
  3. 7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Construction Market Segmentation

Construction By Treatment (USD Million, 2025-2035)

Surgery
Medication
Liposuction
Electrotherapy
Acupuncture
Others

Construction By End User (USD Million, 2025-2035)

Hospital & Clinics
Ambulatory Surgical Centers
Others

Construction By Distribution Channel (USD Million, 2025-2035)

Hospital Pharmacies
Retail Pharmacies
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”